Abstract
Objective
To evaluate the cardotoxicity from recombinant human endostatin (rh-endostatin) combined with chemotherapy.
Methods
A total of 12 cancer patients treated with rhendostatin combined with chemotherapy were selected, and their clinical data collected. Their symptoms, including cardiopalmus, chest distress, dyspnea and changes in their electrocardiogram (ECG), myocardium enzymogram and left ventricular ejection fraction (LVEF), were observed during the drug treatment. These indicators were used for early diagnosis of cardiotoxicity.
Results
Compared with a pre-therapeutic value, there was a significant increase in the CK-MB value at one week after starting the treatment as well as at the end of treatment (P < 0.05). There was a significant change in the ECG at the end of treatment, compared to a pre-therapeutic condition (P < 0.05), but there was no significant difference when comparing the pre-and post-therapeutic LVEF values.
Conclusion
It was recognized that mild cardiac adverse reactions exist in the regimen of recombinant human endostatin combined with chemotherapy. This therapy caused definite injury to the cardiac muscle, but cardiac functions were not obviously changed. CK-MB and ECG may be used as indicators for early monitoring cardiac toxicity. Vigilance against cardiac adverse reactions should be heightened during a course of rh-endostatin combined with chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122–3131.
Wang J, Sun Y, Liu Y, et al. Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhong Guo Fei Ai Za Zhi 2005; 8: 283–290 (Chinese).
Yang L, Wang J, Sun Y, et al. Randomized phase-trial on escalated doses of rh-endostatin (YH-16) for advanced non-small cell lung cancer. Zhong Guo Zhong Liu Lin Chuang 2006; 28: 138–141 (Chinese).
O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–285.
Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332–344.
Ewer MS, Vooletich MT, Durand JB, et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer 2006; 94: 1016–1020.
Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22: 322–329.
Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820–7826.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med 2001; 344: 783–792.
Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215–1221.
Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908–916.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Qin, J., Zhang, P., Qian, X. et al. Analysis of cardiotoxicity from rh-endostatin therapy combined with chemotherapy. Chin. J. Clin. Oncol. 5, 290–293 (2008). https://doi.org/10.1007/s11805-008-0290-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11805-008-0290-1